产品详情
Targets
Target | Value |
---|---|
HER2 | IC50: 59nM |
EGFR | IC50: 92nM |
KDR | IC50: 800nM |
Src | IC50: 1.4μM |
PDK-1 | IC50: >5μM |
IKK2 | IC50: >9μM |
CDK2/CyclinE | IC50: >18μM |
CDK1/CyclinB1 | IC50: >18μM |
C-Raf/MEK1 | IC50: >18μM |
Tpl-2 | IC50: >18μM |
Akt | IC50: >20μM |
c-Met | IC50: >35μM |
MK2 | IC50: >45μM |
CDK4/CyclinD1 | IC50: >50μM |
In vitro (25°C) | DMSO | Warmed: 4 mg/mL (7.18 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 30% PEG400+0.5% Tween80+5% propylene glycol | 4 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 17.95 mL | 89.77 mL | 179.53 mL |
0.5 mM | 3.59 mL | 17.95 mL | 35.91 mL |
1 mM | 1.8 mL | 8.98 mL | 17.95 mL |
5 mM | 0.36 mL | 1.8 mL | 3.59 mL |
*The above data is based on the productmolecular weight 557.0 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10638 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 557.0 |
Formula | C30H29ClN6O3 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 698387-09-6 |
SMILES | CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C |
产品标签
Product Questions
Product Questions
BIBW2992 (Afatinib)
BIBW2992 (Afatinib)是酪氨酸激酶抑制剂(TKI),它不可逆地抑制人表皮生长因子受体2(Her2)和表皮生长因子…
AG-18 (Tyrphostin 23)
AG-18 (Tyrphostin 23)是人表皮癌细胞系A431中的表皮生长因子(EGF)受体激酶抑制剂,IC50值为35M。
ARRY-543 (Varlitinib, ASLAN001)
ARRY-543 (Varlitinib,ASLAN001)是一种新型口服ErbB家族抑制剂,与批准的ErbB抑制剂不同,它直接或间接靶向ErbB家…
Pelitinib (EKB-569)
Pelitinib (EKB-569)是一种有效的,不可逆EGFR抑制剂,IC50为38.5 nM
XL647 (Tesevatinib)
XL647 (Tesevatinib)是一种口服生物可利用的小分子RTK抑制剂,可结合并抑制在肿瘤细胞增殖和肿瘤血管形成中…
ASP8273 (Naquotinib)
ASP8273 (Naquotinib)是不可逆的,第三代,选择性突变的表皮生长因子受体(EGFR)抑制剂,具有潜在的抗肿瘤…